Microarray-based gene expression profiling in pancreatic ductal carcinoma: status quo and perspectives.
BACKGROUND
Pancreatic ductal adenocarcinoma has an extremely poor prognosis. To improve the prognosis, novel molecular markers and targets for earlier diagnosis and adjuvant and/or neoadjuvant treatment need to be identified. One of the key techniques that has been developed to achieve this goal is DNA microarray profiling, which is used to identify the mechanisms of deregulated molecular functions in pancreatic carcinoma cells.


OBJECTIVE
As several studies using microarrays have already been published, this review attempts to compare published data and crossvalidate the results. In addition, the applied techniques are discussed.
Grützmann
Robert
R
Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Technical University of Dresden, Fetscherstrasse 74, Dresden, Germany. Robert.Gruetzmann@mailbox.tu-dresden.de
Saeger
Hans Detlev
HD
Lüttges
Jutta
J
Schackert
Hans Konrad
HK
Kalthoff
Holger
H
Klöppel
Günter
G
Pilarsky
Christian
C
D021441:Carcinoma, Pancreatic Ductal / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D004273:DNA, Neoplasm / Q000032:analysis; D020869:Gene Expression Profiling; D006801:Humans; D020360:Neoadjuvant Therapy; D020411:Oligonucleotide Array Sequence Analysis; D010190:Pancreatic Neoplasms / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D011379:Prognosis
D004273:DNA, Neoplasm